ClinicalChemistry53,No.4,2007667
tissueexpressionofmesothelininavarietyoftissues,mostnotablyinmesothelioma,lung,ovarian,endome-trial,andpancreatictumors(8).Atleast3knownvariantsofthemesothelinfamilyhavebeenreportedintheliter-ature(9,10).Althoughearlystudiesindicatedthatme-sothelinwasnotsoluble(11),recentworkdemonstratedvariants1and3tobesoluble,withvariant1beingthepredominantformdetectedinserum(10,12).Variant3containsa3 frameshiftleadingtoanextendedC-termi-nus,andvariant2containsa24-bpinsertionandcanbedetectedonlyatthemRNAlevel.
Despitetheexpressionofmembrane-boundmesothe-linindifferenttumors,thesesolublemesothelin-relatedpeptides(SMRP)haveproventobeapromisingcancerbiomarkerintheseraofpatientswithtumorsofmesothe-lialorigin(7,10).WereporthereanalyticalvalidationstudiesoftheMESOMARKassay,establishingassayperformanceanditspotentialutilityinaclinicalpatientpopulation.
MaterialsandMethods
mesomarkassay
TheMESOMARKassay(FujirebioDiagnostics,Inc.)usesantibody4H3,whichbindstomesothelinvariants1,2,and3,andantibody569,whichbindstovariant1and3(12).Weperformedtheassayaccordingtothemanufac-turer’sinstructions.Briefly,patientserumsampleswerediluted1:101withtheassaydiluentprovidedandappliedinduplicatetoamicrowellplateprecoatedwithanti-body4H3.Afterincubationfor1hatroomtemperature,plateswerewashed,andantibodyOV569-HRPconju-gatewasaddedfor1h.Afterawashstep,TMBsubstratewasaddedtothereactionwellsfor15min,andthen100 Lofstopsolutionwasadded.Theabsorbanceat450nmwasusedtoquantifytheSMRPconcentrationsbycomparisonwitha6-pointcalibrationcurveestablishedbya4-parameterlogisticfitusingSoftmaxProsoftware(MolecularDevices).Unlessotherwisenoted,allstudieswereperformedwithrepresentativereagentsetsfrom2independentlots.Fouroperatorsweretrainedduringa5-day,10-runtrainingstudybeforethestartofanalyticalMESOMARKtests.
primaryantigenandassaystandardization
MESOMARKvaluesareexpressedasnmol/LandarerelatedtoareferencepreparationmaintainedbyFujirebioDiagnostics,Inc.Thereferencepreparationisarecombi-nantantigen(reactivewithbothOV569and4H3)pro-ducedwithastablytransfectedcellline,OV569-,immu-noaffinitypurified,andquantifiedbyaminoacidanalysis.Thiscelllinehasbeendescribedindetailelsewhere(10).Antigenconcentrationsweremeasuredinnanomolesperliter.Primarycalibratorsandcontrolswerereferencedtothispreparationandrangedfrom0to32nmol/Ltocoverthemajorityoftheexpectedrangeinpatientpopulations.Subsequentlotsofantigen(usedtomanufacturethereagentsetcalibratorsandcontrols)werematchedagainst
theprimarycalibratorsandcontrolsbasedonabsorbancemeasurementintheMESOMARKassay,allowingfortraceabilitytothereferencepreparation.
samples
Serumsamplesforuseinanalyticalstudiesweresup-plementedwithrecombinantOV569-reactiveantigen,whereasserumsamplesforuseintheclinicalstudieswerenotsupplemented.Thelatterwerecollectedfromappar-entlyhealthyvolunteers(n 409),aswellasfrompatientswithseveralmalignantandnonmalignantcon-ditions.Malignantconditionsincludedmesothelioma(n 88),ovariancancer(n 111),lungcancer(n 174),coloncancer(n 50),pancreaticcancer(n 52),andendometrialcancer(n 25).Nonmalignantconditionsincluded 150/90mmHg;hypertensionn 100),(definedexposureastoaasbestosblood(npressure 61),andendometriosis(n 16).Clinicalsampleswerecol-lectedretrospectivelybasedonreporteddiagnosisandblindedtotheoperator.Invalidresultswereaddressedbyretestsofthesampleinquestion.Thesesampleswereobtainedfromcommercialsources(Biochemed)in2004exceptforsamplesfrommesotheliomapatientsandasbestos-exposedindividuals,whichwerekindlysup-pliedbyDr.HarveyPass(KarmanosCancerInstitute,WayneStateUniversity,Detroit,MI).PatientswithahistologicallyconfirmeddiagnosisofmesotheliomaseenattheKarmanosCancerInstitutegaveinformedconsenttohaveserum,plasma,andnormalandtumortissuesamplestakenonthedayofoperativeinterventionfortheirtumors.ThesecaseswereperformedbothattheKarmanosCancerInstituteandtheNationalCancerInsti-tuteinBethesda,Maryland,between1995and2003.Allbloodsamplesweredrawnbeforeanesthesiaorbeforesurgeryintheclinic,whenthepatientwasexaminedbythephysician.Theasbestos-exposedpopulationconsistedofpatientsseenattheCenterforEnvironmentalMedicineinSouthfield,Michigan,who,aftergivinginformedcon-sent,donatedurineandserum.Theseasbestos-exposedpatientsalsofilledoutademographicsquestionnaireandgavepermissionforanalysisoftheirpulmonaryfunctiontestsandradiographicimages.Allpatientsprovidedinformedconsent,andallproceduresandprotocolswereapprovedbytheinstitutionalreviewboard.
analyticalmethods
AnalyticalSensitivity.CalibratorA(theassaydiluent)wasassayedinreplicatesof25foreachreagentsetlot,andthemeanabsorbanceplus2SDwasdeterminedandcom-paredwithacalibrationcurve(preparedinduplicate).Thedetectionlimit(alsocalledthelimitoftheblank)wascalculatedbasedonthelinearsegmentconnectingtheAandBcalibrators.
Imprecision.Within-runandtotalimprecisionvalueswereevaluatedaccordingtoNCCLSProtocolEP5-A(13).Tworeplicateseachof3panelswereassayedin2separateruns
A Clinical observation of the therapy for malignant hydrothorax by intra-thoracic injection…… 隐藏>> A ic svai hetClnialobertonoft heryf alap ormignan t hd...
Controlled-Release Oxycodone Alone or Combined with Gabapentin for Management of Malignant Neuro_专业资料。CiJacre13:08,09hn ne s()—620 CR28 wwsrgrn,o ...
Controlled-Release Oxycodone Alone or Combined with Gabapentin for Management of Malignant Neuro_专业资料。CiJacre13:08,09hn ne s()—620 CR28 wwsrgrn,o ...
热门文档